Back to Archived News
Hansen Medical Receives 11 Additional U.S. Patents for Medical Robotics
Thursday, October 28, 2010
Mountain View, CA -- Hansen Medical, Inc. (Nasdaq: HNSN), a global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, today announced that it has expanded its intellectual property portfolio in medical robotics with the recent issuance of 11 additional U.S. patents.
Certain of the patents provide coverage for Hansen Medical's Sensei® X Robotic Catheter System while others provide innovative solutions for potential future advancements to its robotic technology.
"As we build momentum and draw on our presence in the electrophysiology market and create a second beachhead in the vascular surgery market in the coming year, it is important that the technologies embodied in our core systems and future advancements are protected," said Bruce Barclay, Hansen Medical's president and chief executive officer. "In addition to Hansen's expanding patent portfolio, we share rights to over 240 issued U.S. patents through licensing arrangements with third parties. We believe that a well established intellectual property portfolio will ultimately create greater value for our shareholders in the future."
More specifically, the 11 additional patents received by Hansen are U.S. Patent No. 7,699,835, titled Robotically Controlled Surgical Instruments; 7,713,190, Flexible Instrument; 7,727,185, Coaxial Catheter System; 7,744,608, Robotically Controlled Medical Instrument; 7,744,622, Surgical Instrument; 7,758,569, Interchangeable Surgical Instrument; 7,766,894, Coaxial Catheter System; 7,775,972, Flexible Instrument; 7,789,874, Support Assembly for Robotic Catheter System; 7,789,875, Surgical Instruments; and 7,819,884, Robotically Controlled Medical Instrument.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, develops products and technology using robotics for the accurate positioning, manipulation and control of catheters and catheter-based technologies. The company's Sensei® system and its Sensei X Robotic Catheter System were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in electrophysiology (EP) procedures. The flexible robotic platform is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. The safety and effectiveness of the Sensei and Sensei X systems for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including atrial fibrillation (AF), have not been established. In the European Union, the Sensei and the Sensei X systems are cleared for use during EP procedures, such as guiding catheters in the treatment of AF. Additional information can be found at www.hansenmedical.com.
Forward-Looking Statements
his press release contains forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "believes," "goal," "estimate," and similar words. Hansen Medical intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995.
Hansen Medical, Heart Design, Hansen Medical & Heart Design, and Sensei are registered trademarks of Hansen Medical, Inc. in the United States and other countries.
Back to Archived News
